| 0 (0%) | 01-19 18:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.89 |
1-year : | 15.93 |
| Resists | First : | 11.89 |
Second : | 13.64 |
| Pivot price | 10.56 |
|||
| Supports | First : | 9.06 | Second : | 7.54 |
| MAs | MA(5) : | 10.12  |
MA(20) : | 10.97 |
| MA(100) : | 9.47 |
MA(250) : | 6.91 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 36.1 |
D(3) : | 32.3 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 15.73 | Low : | 2.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FULC ] has closed above bottom band by 34.6%. Bollinger Bands are 11.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.67 - 10.72 | 10.72 - 10.76 |
| Low: | 9.81 - 9.87 | 9.87 - 9.91 |
| Close: | 10.05 - 10.15 | 10.15 - 10.22 |
Sun, 18 Jan 2026
Discipline and Rules-Based Execution in FULC Response - Stock Traders Daily
Sat, 17 Jan 2026
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $7 - 富途牛牛
Mon, 12 Jan 2026
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation - Nasdaq
Wed, 07 Jan 2026
Behavioral Patterns of FULC and Institutional Flows - Stock Traders Daily
Tue, 06 Jan 2026
$FULC stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
Tue, 30 Dec 2025
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 66 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 75.8 (%) |
| Shares Short | 2,990 (K) |
| Shares Short P.Month | 3,560 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -31.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -60 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -8.9 |
| PEG Ratio | 0 |
| Price to Book value | 2.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|